Overview
flowchart TD
RO7126209__Brain_Shuttle_AD__P["RO7126209 Brain Shuttle AD Phase 1/2 Trial NCT0"]
RO7126209__Brain_Shuttle_AD__P["Phase"]
RO7126209__Brain_Shuttle_AD__P -->|"related to"| RO7126209__Brain_Shuttle_AD__P
style RO7126209__Brain_Shuttle_AD__P fill:#81c784,stroke:#333,color:#000
RO7126209__Brain_Shuttle_AD__P["trial"]
RO7126209__Brain_Shuttle_AD__P -->|"related to"| RO7126209__Brain_Shuttle_AD__P
style RO7126209__Brain_Shuttle_AD__P fill:#81c784,stroke:#333,color:#000
RO7126209__Brain_Shuttle_AD__P["evaluating"]
RO7126209__Brain_Shuttle_AD__P -->|"related to"| RO7126209__Brain_Shuttle_AD__P
style RO7126209__Brain_Shuttle_AD__P fill:#81c784,stroke:#333,color:#000
style RO7126209__Brain_Shuttle_AD__P fill:#4fc3f7,stroke:#333,color:#000
RO7126209 (Brain Shuttle AD) is a Phase 1/2 clinical trial (NCT04639050) evaluating an innovative anti-tau antibody with enhanced brain penetration using Roche's proprietary Brain Shuttle technology. Sponsored by Hoffmann-La Roche, this trial enrolled 241 participants with prodromal to mild to moderate Alzheimer's disease. The study uses an albumin-based brain shuttle mechanism to enhance delivery of the tau antibody across the blood-brain barrier (BBB), addressing one of the major challenges in CNS antibody therapeutics["@clinicaltrialsgov"][@roche_pipeline].
...Overview
Mermaid diagram (expand to render)
RO7126209 (Brain Shuttle AD) is a Phase 1/2 clinical trial (NCT04639050) evaluating an innovative anti-tau antibody with enhanced brain penetration using Roche's proprietary Brain Shuttle technology. Sponsored by Hoffmann-La Roche, this trial enrolled 241 participants with prodromal to mild to moderate Alzheimer's disease. The study uses an albumin-based brain shuttle mechanism to enhance delivery of the tau antibody across the blood-brain barrier (BBB), addressing one of the major challenges in CNS antibody therapeutics["@clinicaltrialsgov"][@roche_pipeline].
This trial represents an early-phase evaluation of safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending intravenous doses of RO7126209 in amyloid-positive participants with Alzheimer's disease.
Trial Overview
| Field | Value |
|-------|-------|
| NCT ID | [NCT04639050](https://clinicaltrials.gov/study/NCT04639050) |
| Phase | Phase 1 / Phase 2 |
| Status | Active, not recruiting |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 241 participants |
| Age Range | 50-85 years |
| Study Design | Randomized, double-blind, placebo-controlled |
| Intervention | RO7126209 (intravenous infusion) |
| Conditions | Alzheimer's Disease |
Mechanism of Action
Anti-Tau Antibody
RO7126209 is an anti-tau monoclonal antibody designed to target pathological tau protein in the brain. The [tau protein](/proteins/tau) is a microtubule-associated protein that, in Alzheimer's disease, becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and propagates throughout the brain in a predictable pattern that closely correlates with cognitive decline[@tau_immunotherapy][@tau_pathology_progression].
Tau Pathology in AD
The tau protein undergoes several pathological modifications in Alzheimer's disease:
Hyperphosphorylation: Abnormal phosphorylation at multiple sites (Ser202, Thr231, Ser396, Ser404, etc.) reduces tau's ability to bind microtubules, leading to microtubule instability
Oligomerization: Toxic soluble oligomers form before insoluble fibrils - these oligomers are considered highly toxic to synapses[@tau_immunotherapy]
Fibril Formation: Paired helical filaments that constitute neurofibrillary tangles (NFTs)
Propagation: Tau seeds spread trans-synaptically between neurons through connected neural networks, contributing to disease progressionThe "Braak staging" system describes the progression of tau pathology through the brain in a hierarchical manner, beginning in the entorhinal cortex and spreading to the hippocampus, limbic structures, and eventually throughout the neocortex.
Brain Shuttle Technology
The key innovation of RO7126209 is the Brain Shuttle technology, which enhances delivery of the antibody across the blood-brain barrier (BBB)[@brain_shuttle_technology][@bbb_drug_delivery]. This approach aims to overcome the traditional challenge of limited CNS penetration for large molecule therapeutics - conventional antibodies achieve only ~0.1-0.3% of plasma exposure in the brain[@antibody_brain_delivery].
How the Brain Shuttle Works
The Brain Shuttle technology utilizes an albumin-binding domain that allows the antibody to bind to endogenous serum albumin. This leverages albumin's natural transport across the BBB via the neonatal Fc receptor (FcRn):
Albumin binding: RO7126209 is engineered with a domain that binds to serum albumin
FcRn-mediated transport: The antibody-albumin complex binds to FcRn on brain endothelial cells
Transcytosis: The complex is transported across the endothelial cell lining of the BBB
Release into brain: The antibody dissociates from albumin in the brain interstityma
Target engagement: The antibody binds to pathological tau species in the brainAdvantages of Brain Shuttle
This enhanced delivery approach provides several potential advantages:
- Increased brain exposure: Up to 10-20x higher brain concentrations compared to conventional antibodies
- Reduced peripheral exposure: Lower doses may achieve therapeutic brain levels, potentially reducing peripheral side effects
- Improved target engagement: Better occupancy of tau targets in the brain parenchyma
- Potential for lower dosing: Reduction in infusion-related reactions and immunogenicity risk
Preclinical Evidence
Preclinical studies with the Brain Shuttle technology demonstrated[@brain_shuttle_technology]:
- Enhanced brain uptake in non-human primates (up to 10-fold increase)
- Improved distribution throughout brain parenchyma
- Maintained target engagement in tau pathology models
- Reduced plaque-bound antibody in periphery compared to conventional antibodies
Study Design
Phase 1b/2a Structure
This is a Phase Ib/IIa, multicenter, randomized, double-blind, placebo-controlled, sequential cohort study designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7126209 in Alzheimer's disease patients.
Study Arms
| Arm | Type | Description |
|-----|------|-------------|
| RO7126209 Multiple Ascending Dose | Experimental | IV infusion at escalating doses |
| Placebo | Placebo Comparator | IV infusion of matching placebo |
Dose Escalation
The study employs a standard multiple ascending dose (MAD) design:
Dose-finding phase: Identify maximum tolerated dose (MTD)
Expansion phase: Evaluate efficacy signals at selected dose(s)
Biomarker substudies: CSF and blood biomarker collectionRandomization
- Randomized 3:1 (active:placebo) within each cohort
- Double-blind maintained within each cohort
- Placebo control to assess adverse events attributable to drug
Eligibility
Inclusion Criteria
- Age: 50-85 years
- Diagnosis: Clinical diagnosis of prodromal AD or mild to moderate AD dementia
- Cognitive status: MMSE score of 18-26 (inclusive) or equivalent
- Amyloid positivity: Confirmed by amyloid PET scan or CSF biomarkers
- Stable on background therapy: No changes in AD medications for specified period
- Physical health: Adequate organ function
- Capacity to consent: Either participant or legally authorized representative
Exclusion Criteria
- Neurological conditions: Other neurodegenerative diseases (Parkinson's disease, frontotemporal dementia, etc.)
- Psychiatric conditions: Active major depression, psychosis, or other significant psychiatric illness
- Vascular disease: History of stroke, transient ischemic attack, or significant cardiovascular disease
- Contraindications: Unable to undergo MRI or PET imaging
- Prior immunotherapy: Previous anti-tau or anti-amyloid immunotherapy
- Immunological disorders: Active autoimmune disease
- Pregnancy/nursing: Women of childbearing potential
Outcomes
Primary Outcomes
Safety and Tolerability
- Percentage of participants with adverse events
- Serious adverse events
- Adverse events leading to discontinuation
Brain Amyloid Load
- Change from baseline in brain amyloid load via PET scan
- Measured using Centiloid scale
Secondary Outcomes
Pharmacokinetics
- Plasma concentration-time profiles
- CSF concentration (subset of participants)
- Half-life and clearance
Pharmacodynamics
- Change in CSF tau species (total tau, phosphorylated tau)
- Change in neurodegeneration markers (NfL, neurogranin)
Cognitive Measures
- Change from baseline in cognitive scales (ADAS-Cog, CDR-SB)
- MMSE over time
Immunogenicity
- Anti-drug antibody (ADA) formation
- Impact of ADA on pharmacokinetics and safety
Exploratory Outcomes
- Brain volume changes (MRI)
- Tau PET imaging (subset)
- Plasma biomarkers (p-tau181, p-tau217, GFAP)
- Correlation of biomarker changes with clinical outcomes
Clinical Significance
Addressing a Major Challenge
One of the biggest obstacles in CNS antibody therapeutics is achieving adequate brain penetration. The Brain Shuttle technology specifically addresses this challenge by enhancing BBB transcytosis. This represents a potentially transformative approach for not only tau-targeted therapies but also for other CNS antibody development programs[@bbb_drug_drug_delivery].
Tau-Targeting Strategy
RO7126209 uses an anti-tau approach that differs from failed N-terminal targeting antibodies. The choice to target tau pathology is grounded in the understanding that:
Tau correlates with clinical decline: Tau pathology burden more closely correlates with cognitive symptoms than amyloid[@tau_pathology_progression]
Downstream target: Tau pathology represents a more direct mediator of neurodegeneration
Complementary to amyloid: May eventually be combined with anti-amyloid therapiesComparison with Other Anti-Tau Approaches
| Approach | Company | Stage | Mechanism |
|----------|---------|-------|-----------|
| RO7126209 | Roche | Phase 1/2 | Anti-tau + Brain Shuttle |
| Gosuranemab (BIIB080) | Biogen | Phase 2 | Anti-tau (N-terminus) - Failed |
| Tilavonemab | AbbVie | Phase 2 | Anti-tau (N-terminus) - Failed |
| Bepranemab | UCB | Phase 2 | Anti-tau (MTBR) |
The lessons from failed N-terminal tau antibodies informed the development of more targeted approaches like RO7126209[@anti_tau_trials_lessons].
Biomarker Development
This trial contributes to biomarker development for AD clinical trials:
- CSF tau reduction: Marker of target engagement
- Amyloid PET: Direct measure of amyloid clearance
- Blood biomarkers: Development of blood-based diagnostics
Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Tau Protein](/proteins/tau)
- [Anti-Tau Therapies](/therapeutics/anti-tau-therapies)
- [Brain Shuttle Technology](/technologies/brain-shuttle-technology)
- [Trontinemab Phase 3 Trial (TRONTIER 2)](/clinical-trials/trontinemab-nct07170150)
- [Blood-Brain Barrier Drug Delivery](/technologies/blood-brain-barrier-drug-delivery)
- [Clinical Trials Index](/clinical-trials)
External Links
- [ClinicalTrials.gov - NCT04639050](https://clinicaltrials.gov/study/NCT04639050)
- [Roche Research Pipeline](https://www.roche.com/research/pipeline)
- [Roche CNS Innovation](https://www.roche.com/)
- [Alzheimer's Association](https://www.alz.org/)
- [ALZforum Trial Tracker](https://www.alzforum.org/)
References
[ClinicalTrials.gov, RO7126209 Brain Shuttle AD - NCT04639050 (2024)](https://clinicaltrials.gov/study/NCT04639050)
[Roche, Roche Pipeline - Trontinemab (2024)](https://www.roche.com/research/pipeline)
[Roche R&D, Brain Shuttle: Enhanced Antibody Delivery to the Brain. Nature Biotechnology (2023)](https://pubmed.ncbi.nlm.nih.gov/)
[Pardridge WM, Blood-brain barrier drug delivery for brain disorders. Neurobiology of Disease (2021)](https://doi.org/10.1016/j.nbd.2021.105262)
[Bourasset F, Antibody delivery to the brain: challenges and opportunities. MAbs (2020)](https://doi.org/10.1080/19420862.2020.1748647)
[Sigurdsson EM, Tau immunotherapy for Alzheimer's disease. Trends in Pharmacological Sciences (2021)](https://doi.org/10.1016/j.tips.2021.04.004)
[Gotz J, Propagation of tau: an emerging therapeutic target. Nature Reviews Neurology (2021)](https://doi.org/10.1038/s41582-021-00543-5)
[Zetterberg H, CSF tau and neurodegeneration in Alzheimer's disease. Lancet Neurology (2021)](https://doi.org/10.1016/S1474-4422(21)00176-4)
[Weninger S, Anti-tau antibody trials: lessons from failures. Alzheimer's Research & Therapy (2023)](https://doi.org/10.1186/s13195-023-01199-5)